{"disease":{"id":"spindle-cell-sarcoma","name":"spindle cell sarcoma"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06526897","title":"Evaluation of Chest CT Versus Chest X-Ray for Lung Surveillance After Curative-Intent Resection of High-Risk Truncal-Extremity Soft Tissue Sarcoma","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":1582,"lead_sponsor_name":"ECOG-ACRIN Cancer Research Group","has_results":false},{"nct_id":"NCT06568172","title":"Testing the Addition of an Immunotherapy Drug, Cemiplimab (REGN2810), Plus Surgery to the Usual Surgery Alone for Treating Advanced Skin Cancer","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":420,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT02567435","title":"Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":325,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT05304585","title":"Chemotherapy for the Treatment of Patients With Newly Diagnosed Very Low-Risk and Low Risk Fusion Negative Rhabdomyosarcoma","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":205,"lead_sponsor_name":"Children's Oncology Group","has_results":false},{"nct_id":"NCT04994132","title":"A Study to Compare Early Use of Vinorelbine and Maintenance Therapy for Patients With High Risk Rhabdomyosarcoma","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":118,"lead_sponsor_name":"Children's Oncology Group","has_results":false},{"nct_id":"NCT01962103","title":"Study to Find a Safe Dose and Show Early Clinical Activity of Weekly Nab-paclitaxel in Pediatric Patients With Recurrent/ Refractory Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":107,"lead_sponsor_name":"Celgene","has_results":true},{"nct_id":"NCT04956198","title":"Drug Sensitivity and Mutation Profiling","phase":"","overall_status":"COMPLETED","enrollment_count":14,"lead_sponsor_name":"Florida International University","has_results":false},{"nct_id":"NCT04420975","title":"Nivolumab and BO-112 Before Surgery for the Treatment of Resectable Soft Tissue Sarcoma","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":14,"lead_sponsor_name":"Jonsson Comprehensive Cancer Center","has_results":false},{"nct_id":"NCT05974410","title":"Expanded Access to Immunomodulatory AVM0703 for Solid Tumor and Blood Cancer Patients","phase":"","overall_status":"AVAILABLE","enrollment_count":null,"lead_sponsor_name":"AVM Biotechnology Inc","has_results":false},{"nct_id":"NCT03874455","title":"Tazemetostat Expanded Access Program for Adults With Solid Tumors","phase":"","overall_status":"NO_LONGER_AVAILABLE","enrollment_count":null,"lead_sponsor_name":"Epizyme, Inc.","has_results":false}],"total":10},"guidelines":[],"source":"Drug Landscape verified database"}